The host is primed with four LV305 vaccinations carrying the tumour antigen, alternating with the G305 vaccine-carrying tumour antigen and the TLR4 agonist, glycopyranosyl lipid A, which is a potent dendritic cell activator. Here, TLR4 is linked to neoplasm.